Another VR1 tag team

In the wake of the COX-2 debacle, it's no surprise that Pfizer Inc. is demonstrating an increased interest in alternative mechanisms to treat pain. Last week, PFE announced that it will combine its preclinical vanilloid receptor 1 antagonist program with one from Renovis Inc. Although intellectual property is likely to have been a driver

Read the full 544 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE